Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

John Hendrick

Physician Assistant Charleston, SC Physician Assistant

NPI 1528021896 CMS profile 10841086

2180 Henry Tecklenburg Dr, Charleston, SC 29414

Open in the dashboard

General payments

$10,811

415 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Hendrick of Charleston, SC is reported in the CMS Open Payments database as having received $10,811 across 415 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,558 108
2024 General $3,028 108
2023 General $2,077 85
2022 General $2,285 84
2021 General $864 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Hendrick
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to John Hendrick were reported at $2,558. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year John Hendrick Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $864 $132 $37–$438 $132
2022 $2,285 $155 $48–$522 $149
2023 $2,077 $167 $52–$557 $160
2024 $3,028 $178 $55–$600 $164
2025 $2,558 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $1,329 40 payments
  2. E.R. Squibb & Sons, L.L.C. $1,127 35 payments
  3. Genzyme Corporation $699 30 payments
  4. Incyte Corporation $690 22 payments
  5. Lilly USA, LLC $679 30 payments
  6. AbbVie, Inc. $660 34 payments
  7. Sun Pharmaceutical Industries Inc. $606 34 payments
  8. Galderma Laboratories, L.P. $596 23 payments
  9. Novartis Pharmaceuticals Corporation $582 25 payments
  10. UCB, Inc. $535 22 payments
  11. Other $3,307 120 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,417 409 payments
  2. Education $394 6 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $1,462 37 payments
  2. SOTYKTU $1,127 35 payments
  3. DUPIXENT $991 43 payments
  4. OPZELURA $690 22 payments
  5. TALTZ $552 28 payments
  6. CIBINQO $411 21 payments
  7. Bimzelx $395 15 payments
  8. ILUMYA $386 22 payments
  9. OLUMIANT $348 17 payments
  10. COSENTYX $345 14 payments
  11. Other $5,425 254 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

468

Median for Physician Assistant: 241

Drug cost

$376,069

Median for Physician Assistant: $4,110

Branded share of claims

16.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 55 $214,457
Rinvoq Upadacitinib Brand 24 $153,015
Betamethasone Dipropionate Generic 101 $3,710
Ketoconazole Generic 115 $1,742
Fluorouracil Generic 12 $718
Metronidazole Generic 13 $663
Doxycycline Hyclate Generic 68 $563
Triamcinolone Acetonide Generic 47 $500
Imiquimod Generic 16 $475
Econazole Nitrate Generic 17 $227

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$172,168

Of which drugs: $17,265

Medicare patients

684

Average age 74

Services billed

11,838

330 women, 354 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 42%
Ischemic heart disease 26%
Diabetes 24%
Chronic kidney disease 18%
Cancer 17%
Atrial fibrillation 16%
Osteoporosis 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg J7345 Office 21 7,602 $10,082
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 13 23 $7,151

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $530
$530 — —
TREMFYA
  • Janssen Biotech, Inc. $493
$493 — —
DUPIXENT
  • GENZYME CORPORATION $248
  • Regeneron Healthcare Solutions, Inc. $127
$375 55 —
Bimzelx
  • UCB, Inc. $222
$222 — —
Klisyri
  • Almirall LLC $157
$157 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

415 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record